LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

30.18 1.24

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

29.68

Max

30.27

Pagrindiniai rodikliai
By Trading Economics
Pajamos	10M 32M
Pardavimai	-28M 215M
P/E Sektoriaus vid.	12.169 51.415
Pelnas, tenkantis vienai akcijai	0.786
Pelno marža	15.084
Darbuotojai	293
EBITDA	-2.8M 49M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+44.37% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-139M 1.7B
Ankstesnė atidarymo kaina	28.94
Ankstesnė uždarymo kaina	30.18

Naujienos nuotaikos

By Acuity

17%

83%

23 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-18 23:10; UTC

Karštos akcijos

Stocks to Watch: Agilysys, XP

2026-05-18 18:44; UTC

Pagrindinės rinkos jėgos

Claritev Shares Recover After Comments About DOJ

2026-05-18 23:55; UTC

Uždarbis

Review & Preview: Earnings' Last Gasp -- Barrons.com

2026-05-18 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-18 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-18 23:37; UTC

Rinkos pokalbiai

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

2026-05-18 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

2026-05-18 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

2026-05-18 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

2026-05-18 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

2026-05-18 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

2026-05-18 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-18 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-18 20:25; UTC

Uždarbis

Correct: XP 1Q Total Client Assets BRL1.53T

2026-05-18 20:23; UTC

Uždarbis

XP 1Q Total Client Assets BRL1.53B

2026-05-18 20:19; UTC

Uždarbis

XP 1Q Adj EPS BRL2.49 >XP

2026-05-18 20:19; UTC

Uždarbis

XP 1Q Rev BRL4.73B >XP

2026-05-18 19:10; UTC

Rinkos pokalbiai

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

2026-05-18 19:00; UTC

Uždarbis

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

2026-05-18 18:52; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

2026-05-18 18:17; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

2026-05-18 17:22; UTC

Rinkos pokalbiai

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

2026-05-18 16:57; UTC

Įsigijimai, susijungimai, perėmimai

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

2026-05-18 16:57; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-05-18 16:57; UTC

Rinkos pokalbiai

Commodities Higher as Traders Want Physical Assets -- Market Talk

2026-05-18 16:54; UTC

Įsigijimai, susijungimai, perėmimai

Vinci Doesn't Set Out Financial Details of Deal

2026-05-18 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

2026-05-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

2026-05-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

2026-05-18 16:48; UTC

Įsigijimai, susijungimai, perėmimai

Vinci Buys Canada's Modern Group of Companies

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

44.37% į viršų

12 mėnesių prognozė

Vidutinis 43.44 USD 44.37%

Aukščiausias 72 USD

Žemiausias 28 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

23 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.